Alpha Cognition (ACOG) vs Greenwich LifeSciences (GLSI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Greenwich LifeSciences (GLSI) has outperformed Alpha Cognition (ACOG) over the past year, gaining 32.3% versus a gain of 17.1%. Greenwich LifeSciences is the larger company by market cap ($222.2 million vs $196.9 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ACOG | GLSI |
|---|---|---|
| Share price | $9.04 | $15.14 |
| Market cap | $196.87M | $222.23M |
| 1-day change | 0.00% | -1.62% |
| YTD return | +39.08% | -27.94% |
| 1-year return | +17.10% | +32.28% |
| 5-year return | — | -60.12% |
| EPS (TTM) | $-1.32 | $-1.53 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $10.14 | $34.10 |
| 52-week low | $4.50 | $7.78 |
| Distance from 52-week high | -10.85% | -55.60% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +99.12% | +276.49% |
| Average volume | 125.72K | 138.91K |
| Shares outstanding | 21.78M | 14.68M |
| Employees | 71 | — |
| Sector | Healthcare | Health Care |
| Industry | Biotechnology | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- GLSI has outperformed ACOG by 15.2 percentage points over the past year.
- The two companies sit in different sectors: Alpha Cognition in Healthcare and Greenwich LifeSciences in Health Care.
About Alpha Cognition
ACOG stock →Alpha Cognition Inc., a biopharmaceutical company, engages in the development of treatments for patients suffering from neurodegenerative diseases in the United States and Canada. The company's commercial development program includes ZUNVEYL oral tablet formulation for treating Alzheimer's disease.
Healthcare · Biotechnology · 71 employees
About Greenwich LifeSciences
GLSI stock →Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers in the United States. Its lead product candidate is GP2, a HER2/neu transmembrane peptide, which is in Phase III clinical trial to prevent breast cancer recurrences in patients.
Health Care · Biotechnology: Pharmaceutical Preparations
ACOG vs GLSI FAQ
Which is bigger, Alpha Cognition or Greenwich LifeSciences?
Greenwich LifeSciences (GLSI) is larger, with a market capitalization of $222.23M compared with $196.87M for Alpha Cognition (ACOG).
Which stock has performed better over the past year, ACOG or GLSI?
GLSI returned +32.28% over the past 12 months, compared with +17.10% for ACOG (price return, excluding dividends). Past performance does not predict future results.
Are Alpha Cognition and Greenwich LifeSciences in the same industry?
No. Alpha Cognition is in the Healthcare sector, while Greenwich LifeSciences is in Health Care.